Revolution Medicines (RVMD) Retained Earnings (2019 - 2026)

Revolution Medicines has reported Retained Earnings for 8 years, with the latest figure at -$4.0 billion in Q2 2026.

• On a quarterly basis, Retained Earnings fell 81.82% year-over-year to -$4.0 billion in Q2 2026; TTM through Jun 2026 was -$4.0 billion, a 81.82% decrease from a year earlier, with the FY2025 full-year figure at -$2.9 billion, down 65.1% from the prior year.
• Retained Earnings was -$4.0 billion for Q2 2026 at Revolution Medicines, down from -$3.3 billion in the prior quarter.
• The five-year high for Retained Earnings was -$510.3 million in Q1 2022, with the low at -$4.0 billion in Q2 2026.
• Average Retained Earnings over 5 years is -$1.6 billion, with a median of -$1.4 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings slumped 50.78% in 2023, then tumbled 81.82% in 2026.
• Over 5 years, Retained Earnings stood at -$701.3 million in 2022, then tumbled by 62.22% to -$1.1 billion in 2023, then slumped by 52.75% to -$1.7 billion in 2024, then plunged by 65.1% to -$2.9 billion in 2025, then slumped by 39.42% to -$4.0 billion in 2026.
• The last three Retained Earnings figures came in at -$4.0 billion (Q2 2026), -$3.3 billion (Q1 2026), and -$2.9 billion (Q4 2025), per Business Quant data.